Figure 4 presents an analysis of the groups stratified between inflammatory bowel disease, rheumatic diseases, and a global group, in which the underlying condition of the patients treated with TNF-α inhibitors was not discriminated in the article. The gene discussed is TNF; the disease is rheumatic disorder.